Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial

Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial

(2016) Tsutomu Takashima et al.   LANCET ONCOLOGY

Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02)

(2015) Yeon Hee Park et al.   BREAST CANCER RESEARCH AND TREATMENT

The Global Burden of Cancer 2013

(2015) Christina Fitzmaurice et al.   JAMA Oncology

Estimating QALY Gains in Applied Studies: A Review of Cost-Utility Analyses Published in 2010

(2014) Torbjørn Wisløff et al.   PHARMACOECONOMICS

Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016)

(2013) K. Harano et al.   ANNALS OF ONCOLOGY

Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer

(2013) J. Cortés et al.   ANNALS OF ONCOLOGY

Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer

(2013) Manfred Welslau et al.   CANCER

Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial

(2013) Howard A. Burris et al.   CANCER

Minimal clinically important differences for the EQ-5D and QWB-SA in Post-traumatic Stress Disorder (PTSD): results from a Doubly Randomized Preference Trial (DRPT)

(2013) Quang A Le et al.   Health and Quality of Life Outcomes

Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?

(2013) Amélie Anota et al.   QUALITY OF LIFE RESEARCH

Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial

(2012) Kojiro Shimozuma et al.   SUPPORTIVE CARE IN CANCER

Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer

(2011) Y. Wu et al.   ANNALS OF ONCOLOGY

Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial

(2011) Francesco Nuzzo et al.   BMC CANCER

Comparison of EQ-5D Scores among Anthracycline-Containing Regimens followed by Taxane and Taxane-Only Regimens for Node-Positive Breast Cancer Patients after Surgery: The N-SAS BC 02 Trial

(2011) Takeru Shiroiwa et al.   VALUE IN HEALTH

Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment

(2009) Xiaolei Zhou et al.   BREAST CANCER RESEARCH AND TREATMENT